secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2026-05-13T20:10:24+00:00
Accession:  0001437749-26-016724
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing
--------------------------------------------------------------------

- Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.
- Cash and investments $21.1M as of March 31, 2026.
- Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.
- NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.
- Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/0001437749-26-016724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/acrx20260511_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-016724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer